What IBIMA does

IBIMA (Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina, operating as IBIMA Plataforma BIONAND) is a public, non-profit biomedical research institute headquartered at Málaga Techpark in Andalusia, Spain. Founded in July 2010 through an agreement between the Junta de Andalucía's health department and the University of Málaga, and accredited as a Health Research Institute by Spain's Instituto de Salud Carlos III on January 15, 2015, the institute operates as a multidisciplinary translational research center combining university and clinical-hospital researchers across eight areas: cardiovascular/obesity/diabetes, onco-hematology, neurosciences, autoimmune/allergic diseases, rare diseases (IBIMA-Rare), health technology and innovation (IBIMATech), nanodiagnostics, and advanced nanosystems therapies.

Its core technology infrastructure centers on the BIONAND nanomedicine platform and the Nanoimaging Unit, which holds Singular Scientific and Technological Infrastructure (ICTS) accreditation from the Spanish Ministry of Science and Innovation as an independent node of the NANBIOSIS network. Supporting platforms include a Biobank, genomics, proteomics, metabolomics, bioinformatics, cell culture, histology, and GMP-certified cellular manufacturing facilities. Research output is substantial: principal investigators report individual publication counts of 70–250+ papers, and the institute holds a portfolio of filed patent applications in medical devices and antimicrobials plus additional granted patents in allergy/immunology and pharmaceutical collaborations. Certifications include HRS4R, UNE 166002, AENOR/ISO quality standards, GCP compliance, and ISO 27001.

The business model is grant- and contract-funded rather than commercially productized. Revenue is derived from national competitive grants (ISCIII/FIS), regional government funding (Junta de Andalucía), European Commission framework programmes (Horizon 2020/Horizon Europe projects such as iGAME, SAFE-T, and TransBioLine), pharmaceutical-sponsored clinical trial contracts (GSK, Gilead, Bristol-Myers Squibb, IQVIA), and technology transfer activities. The institute serves four principal constituencies: biomedical and clinical researchers, university researchers and students, regional healthcare providers (Hospital Regional Universitario de Málaga, Hospital Universitario Virgen de la Victoria, Hospital Civil), and the pharmaceutical industry. The management entity is FIMABIS (Fundación para la Investigación de Málaga en Biomedicina y Salud), which handles funding, contracts, HR, and institutional operations.

Name

IBIMA

Legal name

Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND)

Website

https://ibima.eu

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

IBIMA is a public non-profit biomedical research institute in Málaga, Spain, accredited by ISCIII, conducting translational research across eight disease areas and nanomedicine, funded by public grants and pharmaceutical clinical trial partnerships.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)

Keywords

• Biomedical research services
• Nanomedicine platform
• Clinical research trials
• Translational research
• Rare diseases research

Headquarters

HQ city

Málaga

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels3 records

Marketing channels6 records

Core offering

IBIMA Plataforma BIONAND is a non-profit biomedical research institute that conducts multidisciplinary translational research across eight areas (cardiovascular/obesity/diabetes, oncology-hematology, neurosciences, autoimmune/infectious diseases, rare diseases, nanodiagnostics, and advanced nanosystems therapies) and provides specialized research support services through ICTS-accredited platforms including Nanoimaging, Biobank, Genomics, Proteomics, Metabolomics, Bioinformatics, Cell Cultures, Histology, and GMP Cellular Manufacturing. The institute also manages clinical trials, technology transfer activities, and continuous training programs for healthcare and university researchers.

Product overview

IBIMA Plataforma BIONAND is a Health Research Institute (Instituto Sanitario de Investigación) created in July 2010 through an agreement between the Regional Ministry of Health of Andalusia and the University of Málaga. It operates as a multidisciplinary research center combining basic and clinical biomedical research with nanomedicine capabilities. The institute is structured around eight main research areas covering cardiovascular diseases, obesity and diabetes, oncology-hematology, neurosciences, autoimmune diseases, rare diseases (IBIMA-Rare), nanodiagnostics, and advanced nanosystems therapies (IBIMATech). Research support is provided through multiple specialized platforms including Nanoimaging, Biobank, Bioinformatics, Cell Cultures, Genomics, Proteomics, Metabolomics, Histology, and GMP-certified Cellular Manufacturing facilities. The institute also offers clinical research services, innovation and technology transfer programs, international mobility schemes, and continuous professional training through specialized courses and doctoral programs.

Differentiator

Problem solved

Functional benefit

Brands

• IBIMA-Rare: Research area focused on rare diseases
• IBIMATECH
• IBIMA Plataforma BIONAND

Products and services

• Nanoimaging Service (ICTS NANBIOSIS Node)
• Biobank Service
• Clinical Research Services
• GMP Cellular Manufacturing Service
• Multi-Omics Platform Services (Genomics, Proteomics, Metabolomics, Bioinformatics) Specialized omics platforms providing genomics sequencing, proteomics analysis, metabolomics profiling, and bioinformatics support for translational research projects in cardiovascular, oncology, autoimmune, and rare disease areas.
• IBIMA-Rare (Rare Diseases Research Unit)
• IBIMATech (Health Technology and Innovation Area)
• Continuous Training Programs Educational offerings including clinical research diplomas, specialized biomedical courses, workshops, seminars, and doctoral programs for healthcare professionals and researchers.

Quantifiable outcome

• One of more than 30 accredited health research institutes in Spain
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and supporting.

• Junta de Andalucía - Consejería de SaludcoreStrategic or Co-development Partner · 1 July 2010Founding institutional partner that established IBIMA in July 2010 through an agreement with the Regional Ministry of Health. Provides ongoing funding and institutional support for biomedical research activities.
• Universidad de MálagacoreStrategic or Co-development Partner · 1 July 2010Founding academic partner in the July 2010 agreement. Provides university researchers, academic infrastructure, and joint research programs. Researchers from the university work alongside healthcare professionals in the institute.
• Instituto de Salud Carlos IIIcoreStrategic or Co-development PartnerNational health research institute that accredited IBIMA as a Health Research Institute on January 15, 2015. Provides national research funding, FIS grants, and coordinates the network of accredited health research institutes in Spain.
• FIMABIS (Fundación para la Investigación de Málaga en Biomedicina y Salud)coreStrategic or Co-development PartnerManagement body of IBIMA Plataforma BIONAND. Acts as the legal entity handling funding, contracts, HR management, and institutional operations for the research institute.
• Málaga Techpark (Parque Tecnológico de Andalucía)coreOthersTechnology park location hosting IBIMA's main headquarters at Avenida Severo Ochoa. Provides research infrastructure and proximity to other technology and biotechnology companies.
• CIBER (Biomedical Research Networking Centres)coreStrategic or Co-development PartnerIBIMA researchers participate in various CIBER networks including CIBERER (Rare Diseases), CIBEREHD (Hepatology), CIBER of Physiopathology of Obesity and Nutrition, and others, enabling national research collaboration.
• European Clinical Research Infrastructure Network (ECRIN)majorStrategic or Co-development PartnerEuropean network supporting multinational clinical research. IBIMA participates through SCReN (Spanish Clinical Research Network) for international clinical trials.
• SCReN (Spanish Clinical Research Network)majorStrategic or Co-development PartnerSpanish clinical research network of ISCIII that supports and coordinates clinical trials. IBIMA collaborates with SCReN for clinical trial design and execution.
• NANBIOSIS ICTScoreStrategic or Co-development PartnerSingular Scientific and Technological Infrastructure network for nanomedicine. IBIMA's Nanoimaging Unit operates as an independent node of NANBIOSIS, providing access to specialized national infrastructure.
• EURAXESS SpainsupportingOthersEuropean initiative supporting researcher mobility. IBIMA uses EURAXESS portal to attract international talent and provide information on residence permits, social security, and career development for foreign researchers.
• Pharmaceutical companies (various)majorStrategic or Co-development PartnerIBIMA conducts clinical trials sponsored by pharmaceutical companies including GSK, Gilead, Bristol-Myers Squibb, IQVIA, and others. These partnerships provide funding for clinical research and access to novel therapeutics.

Scale indicators17 records

Recent moves9 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/_ibima
• YouTubeyoutube.com/channel/UCY3UUZTi9X0ur-1Gd6MKonw
• Facebookfacebook.com/Ibima.eu
• LinkedInlinkedin.com/company/ibima
• Instagraminstagram.com/_ibima

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBIMA